Compare SPH & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPH | TSHA |
|---|---|---|
| Founded | 1945 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 1996 | 2020 |
| Metric | SPH | TSHA |
|---|---|---|
| Price | $20.21 | $4.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $10.78 |
| AVG Volume (30 Days) | 88.8K | ★ 2.9M |
| Earning Date | 05-07-2026 | 03-19-2026 |
| Dividend Yield | ★ 6.38% | N/A |
| EPS Growth | ★ 42.11 | 5.56 |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $1,432,518,000.00 | $9,773,000.00 |
| Revenue This Year | $2.06 | N/A |
| Revenue Next Year | $1.64 | $637.76 |
| P/E Ratio | $29.54 | ★ N/A |
| Revenue Growth | 7.94 | ★ 17.28 |
| 52 Week Low | $17.30 | $1.13 |
| 52 Week High | $21.72 | $6.02 |
| Indicator | SPH | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 45.83 | 39.34 |
| Support Level | $20.00 | $4.03 |
| Resistance Level | $20.70 | $5.24 |
| Average True Range (ATR) | 0.40 | 0.25 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 14.67 | 3.65 |
Suburban Propane Partners LP distributes propane, renewable propane, renewable natural gas (RNG), fuel oil, refined fuels, and markets natural gas and electricity in deregulated markets. It produces and invests in low-carbon fuel alternatives. The company installs and services home comfort heating and ventilation equipment and distributes fuel oil, kerosene, diesel, and gasoline to about 25,000 residential and commercial customers mainly in the U.S. northeast. It operates three segments: Propane, Fuel Oil and Refined Fuels, and Natural Gas and Electricity, with the Propane segment generating the majority of revenue. Propane, a by-product of natural gas processing and petroleum refining, is a clean-burning energy source known for transportability and ease of use.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.